Van K. Morris, MD

Van Karlyle Morris, MD, discusses the efficacy of nivolumab plus ipilimumab according to stratification factors in dMMR/MSI-H mCRC.

Van Karlyle Morris, MD, discusses data supporting the FDA approval of nivolumab plus ipilimumab for dMMR/MSI-H unresectable or metastatic CRC.

Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer.

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Van K. Morris, MD, discusses the recent progress made in the treatment of patients with BRAF-mutated metastatic colorectal cancer.

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.

Van K. Morris, MD, assistant professor of GI Oncology, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) as a potential treatment for patients with anal cancer.